Jw Holdings (096760) - Net Assets

Latest as of September 2025: ₩567.12 Billion KRW ≈ $384.33 Million USD

Based on the latest financial reports, Jw Holdings (096760) has net assets worth ₩567.12 Billion KRW (≈ $384.33 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.23 Trillion ≈ $833.08 Million USD) and total liabilities (₩662.18 Billion ≈ $448.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Jw Holdings's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩567.12 Billion
% of Total Assets 46.13%
Annual Growth Rate 5.36%
5-Year Change 55.65%
10-Year Change 92.89%
Growth Volatility 18.2

Jw Holdings - Net Assets Trend (2007–2024)

This chart illustrates how Jw Holdings's net assets have evolved over time, based on quarterly financial data. Also explore Jw Holdings assets under control for the complete picture of this company's asset base.

Annual Net Assets for Jw Holdings (2007–2024)

The table below shows the annual net assets of Jw Holdings from 2007 to 2024. For live valuation and market cap data, see Jw Holdings market cap and net worth.

Year Net Assets Change
2024-12-31 ₩521.39 Billion
≈ $353.34 Million
+49.50%
2023-12-31 ₩348.75 Billion
≈ $236.35 Million
+4.65%
2022-12-31 ₩333.26 Billion
≈ $225.85 Million
+9.33%
2021-12-31 ₩304.82 Billion
≈ $206.57 Million
-9.00%
2020-12-31 ₩334.97 Billion
≈ $227.00 Million
-4.73%
2019-12-31 ₩351.62 Billion
≈ $238.29 Million
-12.31%
2018-12-31 ₩401.00 Billion
≈ $271.75 Million
+7.01%
2017-12-31 ₩374.73 Billion
≈ $253.95 Million
+34.99%
2016-12-31 ₩277.59 Billion
≈ $188.12 Million
+2.70%
2015-12-31 ₩270.31 Billion
≈ $183.18 Million
+27.54%
2014-12-31 ₩211.94 Billion
≈ $143.63 Million
-10.20%
2013-12-31 ₩236.03 Billion
≈ $159.95 Million
+14.88%
2012-12-31 ₩205.46 Billion
≈ $139.24 Million
-16.69%
2011-12-31 ₩246.62 Billion
≈ $167.13 Million
+28.15%
2010-12-31 ₩192.45 Billion
≈ $130.42 Million
-12.70%
2009-12-31 ₩220.43 Billion
≈ $149.38 Million
+3.01%
2008-12-31 ₩213.99 Billion
≈ $145.02 Million
-0.34%
2007-12-31 ₩214.73 Billion
≈ $145.52 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Jw Holdings's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 8564615724000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩85.65 Billion 37.31%
Other Components ₩143.90 Billion 62.69%
Total Equity ₩229.54 Billion 100.00%

Jw Holdings Competitors by Market Cap

The table below lists competitors of Jw Holdings ranked by their market capitalization.

Company Market Cap
Taiyen Biotech Co Ltd
TW:1737
$200.69 Million
Dynamix Corporation III Class A Ordinary Shares
NASDAQ:DNMX
$200.85 Million
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
$200.93 Million
Maritime Resources Corp.
V:MAE
$200.98 Million
RCI Hospitality Holdings Inc
NASDAQ:RICK
$200.66 Million
GENFIT S.A. ADR/1 EO-25
F:XUPB
$200.59 Million
X-Legend Entertainment Co Ltd
TW:4994
$200.57 Million
Peninsula Group Ltd
TA:PEN
$200.48 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jw Holdings's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 123,964,559,380 to 229,541,382,040, a change of 105,576,822,660 (85.2%).
  • Net income of 62,617,686,450 contributed positively to equity growth.
  • Dividend payments of 17,170,385,210 reduced retained earnings.
  • Share repurchases of 5,984,334,660 reduced equity.
  • Other factors increased equity by 66,113,856,080.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩62.62 Billion +27.28%
Dividends Paid ₩17.17 Billion -7.48%
Share Repurchases ₩5.98 Billion -2.61%
Other Changes ₩66.11 Billion +28.8%
Total Change ₩- 85.17%

Book Value vs Market Value Analysis

This analysis compares Jw Holdings's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.32x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 1.71x to 1.32x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 ₩2502.52 ₩4280.00 x
2018-12-31 ₩2715.27 ₩4280.00 x
2019-12-31 ₩2255.45 ₩4280.00 x
2020-12-31 ₩2204.75 ₩4280.00 x
2021-12-31 ₩1355.51 ₩4280.00 x
2022-12-31 ₩1480.61 ₩4280.00 x
2023-12-31 ₩1715.63 ₩4280.00 x
2024-12-31 ₩3247.67 ₩4280.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jw Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 27.28%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 7.05%
  • • Asset Turnover: 0.71x
  • • Equity Multiplier: 5.45x
  • Recent ROE (27.28%) is above the historical average (6.88%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2009 0.96% 0.19% 0.78x 6.58x ₩-9.75 Billion
2013 16.91% 3.36% 0.52x 9.63x ₩7.28 Billion
2014 -11.41% -1.91% 0.55x 10.81x ₩-20.53 Billion
2015 0.17% 0.03% 0.58x 10.44x ₩-10.19 Billion
2016 -7.43% -1.27% 0.57x 10.27x ₩-20.32 Billion
2017 32.24% 7.90% 0.51x 8.06x ₩37.26 Billion
2018 12.74% 3.19% 0.57x 7.02x ₩4.99 Billion
2019 -22.36% -4.60% 0.58x 8.31x ₩-48.40 Billion
2020 7.30% 1.37% 0.70x 7.65x ₩-3.94 Billion
2021 -2.98% -0.35% 0.74x 11.43x ₩-12.10 Billion
2022 20.70% 2.56% 0.75x 10.82x ₩11.45 Billion
2023 15.35% 2.05% 0.79x 9.49x ₩6.63 Billion
2024 27.28% 7.05% 0.71x 5.45x ₩39.66 Billion

Industry Comparison

This section compares Jw Holdings's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $401,390,357,055
  • Average return on equity (ROE) among peers: 0.79%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jw Holdings (096760) ₩567.12 Billion 0.96% 1.17x $200.69 Million
Dongwha Pharm.Co.Ltd (000020) $252.93 Billion 10.38% 0.28x $113.83 Million
Yuhan Corp. (000100) $407.93 Billion 10.79% 0.55x $4.57 Billion
Yuhan Corp Preferred (000105) $1.65 Trillion 2.42% 0.28x $59.61 Million
Yuyu Pharma (000220) $69.50 Billion 3.97% 0.28x $46.55 Million
Yuyu Pharma Inc (000225) $117.04 Billion 1.10% 0.32x $17.67 Million
Yuyu Pharma Inc (000227) $78.29 Billion 7.52% 0.42x $42.93 Million
Ildong Holdings Co Ltd (000230) $169.10 Billion -60.53% 4.10x $76.14 Million
Samil Pharm (000520) $127.83 Billion 1.30% 1.90x $127.90 Million
Donga Socio Holdings (000640) $875.86 Billion 17.02% 0.60x $427.15 Million
Jw Pharmac (001060) $265.44 Billion 13.94% 1.43x $476.78 Million

About Jw Holdings

KO:096760 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$200.69 Million
₩296.14 Billion KRW
Market Cap Rank
#16520 Global
#694 in Korea
Share Price
₩4280.00
Change (1 day)
-2.28%
52-Week Range
₩3035.00 - ₩4470.00
All Time High
₩26485.64
About

JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair … Read more